Jazz Pharmaceuticals
JAZZ
508 hedge funds and large institutions have $7.28B invested in Jazz Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 170 increasing their positions, 171 reducing their positions, and 56 closing their positions.
131% more call options, than puts
Call options by funds: $17M | Put options by funds: $7.36M
64% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 56
13% more capital invested
Capital invested by funds: $6.43B → $7.28B (+$842M)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
6% more funds holding
Funds holding: 477 → 508 (+31)
4.19% more ownership
Funds ownership: 93.61% → 97.8% (+4.2%)
1% less repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 171
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$59.8M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$57.1M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$37.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$37.2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$37.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$64.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$54.2M |
| 3 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
-$25.9M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$23.8M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$23.2M |
JAZZ Hedge Fund Activity: Q4 2024 in Review
508 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2024, worth a combined $7.28B — up 13% from $6.43B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new JAZZ positions and 56 closed out — a net gain of 36 holders — while 170 added to existing stakes and 171 trimmed.
The largest buyer was Fuller & Thaler Asset Management, adding an estimated $59.8M. The largest seller was Citadel Advisors, cutting an estimated $64.5M.
- 508 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2024, up from 477 in Q3 2024.
- Funds reported $7.28B of Jazz Pharmaceuticals stock for Q4 2024, up 13% quarter-over-quarter.
- 92 funds opened new Jazz Pharmaceuticals positions in Q4 2024 and 56 closed out, a net change of +36 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2024 was Fuller & Thaler Asset Management, an estimated $59.8M added.
- The largest Jazz Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $64.5M sold.
Based on aggregated 13F filings for Q4 2024.